Rilzabrutinib Improves Platelet Response, Quality of Life in Immune Thrombocytopenia Compared to Placebo
HCPLive
DECEMBER 7, 2024
Notably, participants without platelet responses also experienced improvements in fatigue, which may be due to the monoclonal antibodys anti-inflammatory action.
Let's personalize your content